Literature DB >> 15341678

Prevention and management of early esophageal cancer.

W Michael Korn1.   

Abstract

Early esophageal cancer is defined by its limitation to the esophageal mucosa and submucosa. It has become a curable malignant disease, in sharp contrast to the dismal prognosis of esophageal cancer at advanced stages, which still represents the majority of patients. Understanding the risk factors, establishing surveillance programs for patients at risk, and developing preventative interventions such as dietary and lifestyle changes or pharmacologic interventions hold the potential of reducing the incidence of the disease and of shifting the stage distribution toward early cancer. Endoscopic ultrasound examination is pivotal for distinguishing early from advanced stages of the disease because it allows for accurate assessment of tumor infiltration and regional lymph node involvement. The therapeutic mainstay for early esophageal cancer remains surgery. New, less invasive surgical techniques are being tested that are associated with less morbidity and mortality than standard radical esophagectomies. For patients who are not candidates for surgery, definitive chemoradiation is a viable alternative. New endoscopic ablation techniques, such as endoscopic mucosa resection and photodynamic therapy, are potential alternatives to surgery in patients with cancers limited to the mucosa. For patients with adenocarcinoma of the gastroesophageal junction with submucosal involvement, adjuvant chemoradiation should be considered because of its potential to increase survival.

Entities:  

Mesh:

Year:  2004        PMID: 15341678     DOI: 10.1007/s11864-004-0030-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  82 in total

1.  No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  Estimation of the potential for nitrosation and its inhibition in subjects from high- and low-risk areas for esophageal cancer in southern China.

Authors:  Kun Lin; Wenying Shen; Zhongying Shen; Shushen Cai; Yongning Wu
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

Review 3.  Endosonography in columnar-lined esophagus.

Authors:  I Waxman
Journal:  Gastroenterol Clin North Am       Date:  1997-09       Impact factor: 3.806

4.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

Authors:  A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

5.  Stopping drinking and risk of oesophageal cancer.

Authors:  K K Cheng; S W Duffy; N E Day; T H Lam; S F Chung; P Badrinath
Journal:  BMJ       Date:  1995-04-29

6.  Endoscopic treatment of early oesophageal or gastric cancer.

Authors:  K Takeshita; M Tani; H Inoue; I Saeki; S Hayashi; T Honda; F Kando; N Saito; M Endo
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

7.  A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus.

Authors:  T Nishihira; K Hirayama; S Mori
Journal:  Am J Surg       Date:  1998-01       Impact factor: 2.565

8.  Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus.

Authors:  P K Nijhawan; K K Wang
Journal:  Gastrointest Endosc       Date:  2000-09       Impact factor: 9.427

9.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

10.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

View more
  1 in total

1.  The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Kingo Hirasawa; Toshihoro Misumi; Masaharu Hata; Chikara Kunisaki
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.